Rossella E. Nappi

550 total citations · 2 hit papers
19 papers, 288 citations indexed

About

Rossella E. Nappi is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Rossella E. Nappi has authored 19 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Endocrinology, Diabetes and Metabolism, 9 papers in Genetics and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Rossella E. Nappi's work include Menopause: Health Impacts and Treatments (15 papers), Estrogen and related hormone effects (9 papers) and Phytoestrogen effects and research (4 papers). Rossella E. Nappi is often cited by papers focused on Menopause: Health Impacts and Treatments (15 papers), Estrogen and related hormone effects (9 papers) and Phytoestrogen effects and research (4 papers). Rossella E. Nappi collaborates with scholars based in Italy, Spain and United States. Rossella E. Nappi's co-authors include Genevieve Neal-Perry, Marci English, Nanette Santoro, Wendy Wolfman, Rebecca C. Thurston, Santiago Palacios, Petra Stute, Nancy Martin, Marla Shapiro and Misun Lee and has published in prestigious journals such as JAMA, The Journal of Clinical Endocrinology & Metabolism and Obstetrics and Gynecology.

In The Last Decade

Rossella E. Nappi

15 papers receiving 277 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT

2023 96 citations Nancy Martin, Rossella E. Nappi et al. The Journal of Clinical Endocrinology & Metabolism profile →
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause

2024 39 citations JoAnn V. Pinkerton, James A. Simon et al. JAMA profile →

Peers

Countries citing papers authored by Rossella E. Nappi

Since Specialization

Citations

This map shows the geographic impact of Rossella E. Nappi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rossella E. Nappi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rossella E. Nappi more than expected).

Fields of papers citing papers by Rossella E. Nappi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rossella E. Nappi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rossella E. Nappi. The network helps show where Rossella E. Nappi may publish in the future.

Co-authorship network of co-authors of Rossella E. Nappi

This figure shows the co-authorship network connecting the top 25 collaborators of Rossella E. Nappi. A scholar is included among the top collaborators of Rossella E. Nappi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rossella E. Nappi. Rossella E. Nappi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Management of sexual dysfunction in menopause: an update on evidence-based strategies 2025 ·Expert Review of Endocrinology & Metabolism ·(unknown), Laura Cucinella, Rossella E. Nappi	0
2	Targeting vasomotor symptoms with the new drug fezolinetant – an expert overview 2025 ·Gynecological Endocrinology ·Rossella E. Nappi, Angelo Cagnacci, Costantino Di Carlo, Alessandro D. Genazzani, Paola Villa, Tommaso Simoncini	0
3	Sexual function after menopause: the role of vaginal estrogens 2025 ·Maturitas ·Laura Cucinella, Chiara Cassani, Ellis Martini, (unknown), (unknown), (unknown), (unknown), Rossella E. Nappi	2
4	Genitourinary syndrome of menopause (GSM): recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024) 2025 ·Sexual Medicine Reviews ·James A. Simon, Rossella E. Nappi, Peter Chedraui, Amanda Clark, Anne Gompel, (unknown), Santiago Palacios, Wendy Wolfman	0
5	The Role of Vaginal Oestrogen Therapy in Postmenopausal Women With Pelvic Organ Prolapse: Does It Have Any Impact on Perioperative Outcomes? A Systematic Review of Randomised Controlled Trials 2025 ·BJOG An International Journal of Obstetrics & Gynaecology ·(unknown), Salvatore Giovanni Vitale, Maurizio Nicola D’Alterio, (unknown), (unknown), Anna Maria Fulghesu, Rossella E. Nappi, Stefano Angioni	1
6	Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause 2024 ·Expert Opinion on Drug Metabolism & Toxicology ·Laura Cucinella, Sara Tedeschi, (unknown), Chiara Cassani, Ellis Martini, Rossella E. Nappi	1
7	Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause breakdown → 2024 ·JAMA ·JoAnn V. Pinkerton, James A. Simon, Hadine Joffe, Pauline M. Maki, Rossella E. Nappi, Nick Panay, Cláudio N. Soares, Rebecca C. Thurston, (unknown), Claudia Haberland, (unknown), Ulrike Krahn, Uwe Mellinger, Susanne Parke, Christian Seitz, Lineke Zuurman	39
8	Obesity and menopause 2024 ·Gynecological Endocrinology ·Santiago Palacios, Peter Chedraui, Rafael Sánchez‐Borrego, Pluvio Coronado, Rossella E. Nappi	21
9	Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause 2023 ·Obstetrics and Gynecology ·Genevieve Neal-Perry, Antonio Cano, Samuel Lederman, Rossella E. Nappi, Nanette Santoro, Wendy Wolfman, Marci English, (unknown), Udaya Valluri, (unknown)	59
10	Expert opinion on the treatment of vulvovaginal atrophy with ospemifene based on new evidence 2023 ·Climacteric ·Santiago Palacios, Rossella E. Nappi, María Jesús Cancelo Hidalgo, (unknown), Tommaso Simoncini	10
11	Using advanced analytics to help identify women who are more likely to have a severe subjective experience of vulvovaginal atrophy: a modeling study 2023 ·Gynecological Endocrinology ·Rossella E. Nappi, Nicholas Panay, Santiago Palacios, (unknown), (unknown), Martire Particco, Dan Atkins	2
12	Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice 2023 ·Maturitas ·Nick Panay, Rossella E. Nappi, Petra Stute, Santiago Palacios, Tomasz Paszkowski, Risa Kagan, David F. Archer, Julie Héroux, Mitra Boolell	5
13	Is now the time to reconsider risks, benefits, and limitations of estrogen preparations as a treatment for menstrually related migraine? 2023 ·Expert Review of Neurotherapeutics ·Lara Tiranini, Laura Cucinella, Silvia Martella, David Bosoni, Ellis Martini, Rossella E. Nappi	1
14	Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT breakdown → 2023 ·The Journal of Clinical Endocrinology & Metabolism ·(unknown), Nancy Martin, Rossella E. Nappi, Genevieve Neal-Perry, Marla Shapiro, Petra Stute, Rebecca C. Thurston, Wendy Wolfman, Marci English, (unknown), Misun Lee, Nanette Santoro	96
15	Profile of Brazilian climacteric women: results from the Brazilian Menopause Study 2022 ·Climacteric ·Luciano de Melo Pompei, Rogério Bonassi Machado, Marcelo Luis Steiner, (unknown), Nilson Roberto de Melo, Rossella E. Nappi, César Eduardo Fernandes	3
16	The 2022 hormone therapy position statement of The North American Menopause Society: no news is good news 2022 ·The Lancet Diabetes & Endocrinology ·Rossella E. Nappi	6
17	Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey 2022 ·Maturitas ·Rossella E. Nappi, Emad Siddiqui, Lora Todorova, (unknown), E. Gemmen, Neil M. Schultz	32
18	Dietary underreporting by women with Polycystic Ovary Syndrome (PCOS) 2016 ·European Journal of Obstetrics & Gynecology and Reproductive Biology ·(unknown), Rachele De Giuseppe, David Bosoni, Rossella E. Nappi, Hellas Cena	0
19	Results of the European REVIVE (REal Women's VIew of Treatment Options for Menopausal Vulvar/Vaginal ChangEs) survey 2015 ·Maturitas ·Rossella E. Nappi, Santiago Palacios, Nick Panay, T. Rabe, Michael Krychman, Martire Particco	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact